Comparison · NCT02320396-074ae8a3
Desloratadine vs Placebo: Number of Participants Who Discontinue Study Drug Due to an AE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Desloratadine vs Placebo: Number of Participants Who Discontinue Study Drug Due to an AE. Trial comparisons, record NCT02320396-074ae8a3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02320396-074ae8a3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00897 | 0.00246 | 0.0321 | wilson | |
| Risk in group 2 | 0.00889 | 0.00244 | 0.0318 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0000797 | -0.0238 | 0.0241 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.143 | 7.1 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.141 | 7.23 | log | |
| Number needed to treat, for one more participant with the outcome on Desloratadine than on Placebo | 12,500 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Desloratadine | After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) PO QD in the morning for 2 weeks during the Treatment Period. | 2 | 223 | OG000 |
| Group 2 | Placebo | After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period. | 2 | 225 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Discontinue Study Drug Due to an AE
- Description
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE.
- Time frame
- Up to 2 weeks
- Population
- APaT; all participants who received ≥1 dose of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)
- NCT number
- NCT02320396
- Phases
- PHASE3
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Desloratadine 5 mg, Placebo
- Lead sponsor
- Organon and Co
- Results first posted
- 2016-05-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02320396?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02320396-074ae8a3